Positive Correlation With Patient-Reported Outcomes Seen in Phase III ENLIVEN Trial

Jan 24, 2019

Hans Gelderblom, MD, PhD, discusses the correlation between the overall response rate by Tumor Volume Score and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib. 

Hans Gelderblom, MD, PhD, professor of medical oncology at Leiden University Medical Centre, discusses the correlation between the overall response rate by Tumor Volume Score (TVS) and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.

In the phase III ENLIVEN trial, there was a 39% response rate by RECIST criteria in patients randomized to pexidartinib. However, these patients also had a 56% response rate by TVS criteria, says Gelderblom.

Related Content